Pacylex Pharmaceuticals
Manufacturing · Canada · 1-10 Employees
View Company Info for Free
Overview
Headquarters
16205 2a St NE, Edmonton, Alberta, T5Y 3...Phone Number
(780) 264-4295Website
www.pacylex.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Pacylex Pharmaceuticals
Pacylex is a pharmaceutical company targeting hematologic and solid cancers with a new first-in-class therapeutic, headquartered in Edmonton, Alberta, Canada. Pacylex's technology combines new insights from Dr. Luc Berthiaume of the University of Alberta, connecting myristoylation to cancer, with a family of high quality myristoylation inhibitors Pacylex licensed from the University of Dundee. PCLX-001 is the lead drug in a new class of NMT inhibitors, enabling Pacylex to exploit NMTs as new clinical targets for cancer treatment. Pacylex has received regulatory authorization to begin clinical studies in Canada in the spring of 2021 in diffuse large B-cell lymphoma and solid tumors. Pacylex is also receiving support from an Alberta Innovates AICE grant in 2020, and the research leading to this breakthrough was supported in part by the Alberta Cancer Foundation and the Cure Cancer Foundation.Explore more
Pacylex Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Pacylex Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Pacylex Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Pacylex Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Check out if Pacylex Pharmaceuticals is spiking on competitors!
Earning: See what the market has to say on Pacylex Pharmaceuticals recently announced quarterly report
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Pacylex Pharmaceuticals
Click to see if Pacylex Pharmaceuticals had a recent Job posting/layoffs
Product Launch: Get notified when Pacylex Pharmaceuticals launches new products
Funding: Get notified immidiatlly once Pacylex Pharmaceuticals has new funding data
Recommended Actions
Reach out to Masked Content who joined Pacylex Pharmaceuticals as Masked Content
Find 2 more new buyers
Compare Similar Companies to Pacylex Pharmaceuticals
Compare insights from companies similar to Pacylex Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Pacylex Pharmaceuticals
<$5M
1-10
Private
<$5M
2012
LB
Luc BerthiaumeChief Scientific Officer and Co-founder
Company Profile Activity
Activity Insights
Pacylex Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Pacylex Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Pacylex Pharmaceuticals.
Pacylex Pharmaceuticals financials insights
Gather financial insights about Pacylex Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Other Financing Round
$3.9M
Pacylex Pharmaceuticals Tech Stack
A closer look at the technologies used by Pacylex Pharmaceuticals
Most Recent Scoops
Person-Based
Person-Based
Award
Award, Product Management, Customer Service
Award
Pacylex Pharmaceuticals News & Media
Pacylex Pharmaceuticals's Zelenirstat Shows Potent in vitro Radiosensitization in Human Glioblastoma Models
Edmonton, Alberta--(Newsfile Corp. - October 3, 2023) - Pacylex Pharmaceuticals, a clinical stage pharmaceutical company focused on the development of therapies for hematologic and solid cancers, announced recent results generated at NIH using its lead drug, zelenirstat, presented at the Canadian Association of Radiation Oncology Annual Meeting in Montreal, Canada, on September 23, 2023. To view the full announcement, including downloadable images, bios, and more, click here. ...Pacylex Pharmaceuticals Announces First Patient Dosed in a Phase 2a Study of PCLX-001 in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
Edmonton, Alberta--(Newsfile Corp. - May 18, 2023) - Pacylex Pharmaceuticals, a clinical-stage company developing PCLX-001, a first-in-class oral investigational small molecule for leukemia, lymphoma, and solid tumor cancers, today announced the first patient has been dosed in a Phase 2a expansion study in patients with relapsed/refractory B-cell Non-Hodgkin Lymphoma (R/R NHL). To view the full announcement, including downloadable images, bios, and more, click here. ...Pacylex Granted FDA Fast Track Designation for PCLX-001 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Edmonton, Alberta--(Newsfile Corp. - November 22, 2022) - Pacylex, a clinical-stage N-myristoyltransferase (NMT) inhibitor company developing first-in-class therapies for leukemia, lymphoma, and solid tumor cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted PCLX-001 Fast Track Designation for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML). Fast Track is a...Pacylex Will Present Phase 1 Clinical Experience with PCLX-001 and Rationale for Expanding into Acute Myeloid Leukemia Patients at ASH 2022
Edmonton, Alberta--(Newsfile Corp. - November 3, 2022) - Pacylex today announced that data from the ongoing Phase 1 dose escalation clinical trial of PCLX-001, an N-myristoyltransferase (NMT) inhibitor, as well as the scientific rationale for its use in acute myeloid leukemia (AML) patients, will be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition from 10-13 December 2022. The ongoing study is...
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Pacylex Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Pacylex is a pharmaceutical company targeting hematologic and solid cancers with a new first-in-class therapeutic, headquartered in Edmonton, Alberta, Canada. Pacylex's technology combines new insights from Dr. Luc Berthiaume of the University of Alberta, connecting myristoylation to cancer, with a family of high quality myristoylation inhibitors P... Read More
